DRIO · DarioHealth Corp. · Documents

$2.38 -0.35 (-12.84%) At close · Nov 6 Q1 2026 earnings call transcript

Market Cap

$23.27M

9.80M

Volume · Nov 6 14.9K Avg daily vol (3M) 38.18K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $22.36M down 17.3% 10-K filed Mar 19, 2026 Quarterly report FY2026 Q2 Revenue $5.18M down 3.6% 10-Q filed Aug 11, 2026 Latest results Financial results 8-K filed Jul 24, 2023 Earnings call Q1 2026 earnings call Held Mar 31, 2026

2026

Nov 6

Current report 8-K Events of Nov 3

John R. Palumbo appointed Chairman effective immediately

DarioHealth Corp. appointed John R. Palumbo Chairman effective immediately on November 3, 2026, succeeding Yoav Shaked, who will continue serving as a member of the Board.

Director or officer change, or executive pay

Source passage

On November 3, 2026, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, the Board appointed John R. Palumbo as Chairman of the Board, effective immediately, succeeding Yoav Shaked, who will continue to serve as a member of the Board. Open the document at this passage

Sep 4

Current report 8-K Events of Sep 2

Director or officer change, or executive pay AI summary on its way

Aug 21

Current report 8-K Events of Aug 20

Director or officer change, or executive pay AI summary on its way

Aug 11

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $5.18M ▼ 3.6% Net loss $7.92M Diluted EPS $0.85 ▼ 76.0%

Jul 22

Current report 8-K

Entered into a material agreement, Other events AI summary on its way

Jul 10

Current report 8-K

Director or officer change, or executive pay AI summary on its way

May 13

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Revenue $5.58M ▼ 17.3% Net loss $8.25M Diluted EPS $1.25 ▼ 56.4%

Apr 13

Current report 8-K Events of Apr 10

Director or officer change, or executive pay, Other events AI summary on its way

Mar 31

Earnings call

Q1 2026 earnings call AI summary on its way

Mar 30

Current report 8-K

Entered into a material agreement AI summary on its way

Mar 19

Annual report 10-K FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Revenue $22.36M ▼ 17.3% Net loss $41.71M Diluted EPS $10.12 ▼ 17.5%

Mar 19

Registration statement S-3

Registration statement AI summary on its way

Feb 2

Current report 8-K

Charter or bylaw amendment, or fiscal year change AI summary on its way

Jan 29

Current report 8-K

Shareholder vote results AI summary on its way

2025

Dec 31

Earnings call

Q4 2025 earnings call

Dec 29

Registration statement S-3/A

Registration statement

Dec 22

Proxy statement DEF 14A Meeting Jan 29, 2026

Proxy statement

Dec 22

Annual report to holders ARS

Annual report to holders

Dec 11

Proxy statement PRE 14A

Proxy statement

Nov 13

Quarterly report 10-Q FY2025 Q3, ended Sep 30

Quarterly report for FY2025 Q3

Revenue $5.01M ▼ 32.5% Net loss $10.47M Diluted EPS $2.96 ▼ 39.7%

Nov 10

Current report 8-K Events of Nov 5

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Oct 20

Registration statement S-3

Registration statement

Sep 30

Earnings call

Q3 2025 earnings call

Sep 25

Current report 8-K

Entered into a material agreement, Unregistered sale of equity, Charter or bylaw amendment, or fiscal year change, Other events

Sep 19

Current report 8-K Events of Sep 18

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change

Sep 12

Current report 8-K

Other events

Aug 25

Current report 8-K

Charter or bylaw amendment, or fiscal year change, Other events

Aug 12

Quarterly report 10-Q FY2025 Q2, ended Jun 30

Quarterly report for FY2025 Q2

Revenue $5.37M ▼ 14.2% Net loss $12.99M Diluted EPS $0.18 ▲ 125.0%

Jul 31

Registration statement S-3

Registration statement

Jul 23

Current report 8-K

Shareholder vote results

Jul 10

Current report 8-K

Director or officer change, or executive pay

Jun 30

Earnings call

Q2 2025 earnings call

May 30

Proxy statement DEF 14A Meeting Jul 23, 2025

Proxy statement

May 29

Current report 8-K Events of May 23

Entered into a material agreement, Unregistered sale of equity, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change

May 28

Registration statement S-3

Registration statement

May 21

Current report 8-K Events of May 20

Charter or bylaw amendment, or fiscal year change

May 20

Proxy statement PRE 14A

Proxy statement

May 14

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $6.75M ▲ 17.3% Net loss $9.23M Diluted EPS $0.14 ▼ 30.0%

May 6

Current report 8-K Events of Apr 30

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

Apr 28

Current report 8-K

Shareholder vote results

Apr 21

Current report 8-K Events of Apr 18

Director or officer change, or executive pay

Mar 31

Earnings call

Q1 2025 earnings call

Mar 19

Current report 8-K Events of Mar 18

Delisting notice or listing transfer

Mar 14

Current report 8-K Events of Mar 12

Director or officer change, or executive pay

Mar 10

Proxy statement DEF 14A Meeting Apr 28, 2025

Proxy statement

Mar 10

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $27.04M ▲ 32.9% Net loss $42.75M Diluted EPS $0.61 ▼ 68.4%

Feb 28

Proxy statement PRE 14A

Proxy statement

Feb 27

Current report 8-K Events of Feb 24

Director or officer change, or executive pay, Other events

Jan 22

Current report 8-K Events of Jan 21

Other events

Jan 10

Current report 8-K Events of Jan 7

Entered into a material agreement, Unregistered sale of equity

Showing 1–50 of 163 documents

Key facts CIK 1533998 CUSIP 23725P308 13F (30d) 12 filings 6 filers Visit website Investor relations